Applied therapeutics announces topline results from the arise-hf phase 3 study of at-001 in diabetic cardiomyopathy

At-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months

APLT Ratings Summary

APLT Quant Ranking